MiRXES
Singapore, Singapore· Est.
RNA‑based diagnostics company delivering early‑cancer blood tests and NGS tissue profiling.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
AI Company Overview
RNA‑based diagnostics company delivering early‑cancer blood tests and NGS tissue profiling.
OncologyInfectious Diseases
Technology Platform
Proprietary miRNA detection using ID3EAL RT‑qPCR coupled with NGS‑based tissue profiling for comprehensive genomic analysis.
Opportunities
Expansion into North America and Europe, development of multi‑cancer screening panels, and leveraging AI‑driven miRNA analytics for broader disease indications.
Risk Factors
Regulatory approval timelines, reimbursement uncertainty, and intense competition from larger liquid‑biopsy and NGS players.
Competitive Landscape
Competes with GRAIL, Guardant Health, Freenome, and other early‑cancer detection firms; differentiation stems from its miRNA‑focused platform and integrated NGS tissue services.